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ABSTRACT 
Recrystallization of amorphous drugs is currently limiting the simple approach to improve solubility 
and bioavailability of poorly water-soluble drugs by amorphization of a crystalline form of the drug. 
In view of this, molecular mobility, α-relaxation and β-relaxation processes with the associated 
transition temperatures Tgα and Tgβ, was investigated using dynamic mechanical analysis (DMA). The 
correlation between the transition temperatures and the onset of recrystallization for nine amorphous 
drugs, stored at dry conditions at a temperature of 296 K, was determined. From the results obtained, 
Tgα does not correlate with the onset of recrystallization at the experimental storage conditions. 
However, a clear correlation between Tgβ and the onset of recrystallization was observed. It is shown 
that at storage temperature below Tgβ, amorphous nifedipine retains its amorphous form. Based on 
the correlation, an empirical correlation is proposed for predicting the onset of recrystallization for 
drugs stored at 0% RH and 296 K. 
Keywords: Amorphous materials, crystal growth, α-relaxation and β-relaxation, dynamic 
mechanical analysis (DMA), physical stability, glass transition 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
The use of amorphous, rather than crystalline, form of drugs in the formulation of active 
pharmaceutical ingredients to oral dosage forms has gained significant interest due to the apparent 
increase in solubility of the amorphous form compared to their crystalline counterparts. This is indeed 
a promising approach to overcome the poor water solubility challenge that an estimated 70% of 
pharmacologically relevant new chemical compounds suffer from1, which impedes their development 
to oral dosage forms. However, since amorphous solids are thermodynamically unstable, they tend to 
undergo spontaneous crystallization, limiting their overall utility. Despite the significant research 
interest in this area, there is only a hand-full of often complex methods attempting to predict the onset 
of recrystallization of amorphous drugs 2-3. Physical instability (here expressed as the onset of 
recrystallization), is the rate-limiting step in the development of neat amorphous drugs for routine use 
in oral dosage forms, such as tablets or capsules. The conversion from the amorphous form to the 
crystalline form is influenced inter alia by the relative humidity the amorphous form is exposed to 4, 
thermodynamic parameters 5-9, thermal history 10 and the preparation technique used 11. The molecular 
processes involved in recrystallization are complex and the thermal and thermodynamic parameters, 
which have been well studied, do not give sufficient information on this complex process. This leaves 
molecular mobility as a possibly relevant parameter in the recrystallization process 12-13. 
Molecular mobility comprises of intramolecular and intermolecular motions that can be vibrational, 
translational, and/or rotational 14. Generally, amorphous compounds exhibit two types of molecular 
mobility (relaxation), termed global and local mobility. The global mobility is also called primary (α-
) relaxation and is responsible for the glass transition temperature, Tgα, 12, 15. The physics of the Tgα 
have not been fully explored, however, it is the temperature at which molecular mobility is 
cooperative in nature leading to a change from a glassy form to the rubbery (super-cooled melt) form 
16. In the amorphous pharmaceutical field, the Tgα is mostly studied using differential scanning 
calorimetry (DSC) 17. At the Tgα, which we must emphasize as a temperature range rather than a 
single temperature, there is a substantial sigmoidal change in the heat capacity of the sample resulting 
in an increase in the total heat flow.  
The local mobility, also called secondary (β-) relaxation, has a lower activation energy compared to 
the α-relaxation 18 and is therefore observed at temperatures below the Tgα 16 and classified as a sub-
Tgα relaxation. The study of β-relaxation and crystallization processes are of prime importance as it 
has been shown that there might be a connection between these two processes 19-25. In this study, 
dynamic mechanical analysis (DMA) was used to probe temperature dependent mechanical response 
of nine amorphous drugs, five of which were made amorphous by quench cooling (QC) and four were 
already amorphous drugs. DMA is a technique used to analyze the mechanical properties of a material 
as a function of temperature or time, and temperature-dependent discontinuities in these phenomena 
arising from the amorphous glass transitions are readily apparent with this method. In the isochronal 
mode (fixed frequency temperature ramping), an oscillatory stress is applied to the sample at a 
selected frequency and the resulting strain is measured. The difference in the phase angle between 
stress and strain is measured and mechanical properties such as viscosity (loss modulus E''), elasticity 
(storage modulus E') and the damping parameter (tan δ) can be determined as a function of 
temperature 26-30. It is important to note that DMA does not probe the fundamental dielectric 
relaxations (which are measured using electromagnetic radiation), but rather the mechanical response 
of materials that exhibit the same temperature-dependence as these motions due to a fundamental 
dependence of both properties on the bulk potential energy landscape.31 
The objective of this study is to characterize the temperature dependent mobility of a set of amorphous 
drugs and determine which of the transition temperatures is responsible for the crystallization of the 
set of amorphous drugs upon storage at 0% RH. 
METHODS AND MATERIALS 
 Materials 
Nine drugs were chosen for this study. Indomethacin was obtained from Fagron (Copenhagen, 
Denmark), nifedipine from Hangzhou Dayangchem Co. Ltd (Hangzhou, China), carvedilol from 
Cipla Ltd (Mumbai, India), cimetidine from Hawkins (Minneapolis, USA), celecoxib from Dr. 
Reddy’s (Hyderabad, India), the marketed amorphous drug; zafirlukast, from Godenbridge Pharma, 
Inc (California, USA), Na Taurocholate from Sigma-Aldrich (Steinheim, Germany), Zent X and Zent 
V from Zentiva k. s. (Prague, Czech Republic). 
 Preparation of amorphous drugs 
The crystalline drugs were melted in aluminum pans at approx.10 K above their melting points on a 
hot plate. The melts were allowed to cool on a cold surface at RT and milled with mortar and pestle 
to obtain powders for subsequent analysis. The already amorphous drugs were used as received. 
 X-ray powder diffraction (XRPD) 
XRPD measurements were performed using a PANalytical X-Pert PRO X-ray diffractometer (Almeo, 
Netherlands). The samples were exposed to Cu K-α radiation (λ=1.54187 Å) using a voltage of 45 
kV and current of 40 mA. All measurements were performed in reflection mode from 5 – 30° 2θ 
using a scanning speed 0.058° 2θ/s and a step size of 0.026° 2θ. 
 Physical stability studies 
Physical stability studies were performed on the quench cooled amorphous drugs. The samples were 
stored at 0% RH using phosphorous pentoxide (P2O5) at 298 K. XRPD measurements for the first 
sample set were performed on a weekly basis for the first 8 weeks. Samples that did not show signs 
of crystallization were measured monthly from then on. The second set of samples, amorphous 
nifedipine stored at 0% RH at different temperatures (273 K, 296 K and 313 K), was measured on 
day 1, 4, 7 and weekly from then on. For nifedipine stored at 0% RH at 253 K and 193 K, XRPD 
measurements were made monthly. For the physical stability of the already (practically stable) 
amorphous drugs used, the onset of recrystallization (1/time) was set to 1e-7.  
 Dynamic mechanical analysis (DMA) 
Powdered amorphous drugs were evenly loaded onto the lower tray of a stainless-steel powder pocket. 
With the powder pocket lid in place, the sample was loaded into a 35 mm dual cantilever clamp of a 
DMA Q800 (TA Instruments- Waters LLC, New Castle, DE, USA) fitted with a gas cooling 
accessory connected to a liquid nitrogen dewar. The DMA detects mechanical changes using an 
optical encoder (approx. 1nm resolution) and are more sensitive towards detection of glass transitions 
than heat capacity changes as in a DSC. 
DMA scans were performed in a multi-frequency-strain mode where the sample is heated linearly 
whilst deforming the sample in an oscillatory manner. Measurements were performed at a frequency 
of 1 Hz, amplitude of 20.00 µm and a heating rate of 3 K/min from 153 K up to the DMA measured 
glass transition temperature, of the sample. Once the β-relaxation region was observed, repeated 
measurements were made in triplicate starting at approximately 20 K below the onset of β-relaxation. 
Data analysis was performed using Trios® software. 
 
 
RESULTS AND DISCUSSION 
The data obtained from the DMA measurements of the model drugs, as shown in Figure 1 for 
amorphous indomethacin, is from the tan δ signal. Upon freezing at 153 K and reheating the 
amorphous drugs at a heating rate of 3 K/min, a sharp peak is observed and its maximum was taken 
as Tgα. In the sub-Tgα range a broad peak was also observed which is assigned to the β-relaxation.  
  
Figure 1: Tan δ response for amorphous indomethacin. The insert is a zoomed-in section from 
173 K to 273 K which shows the β-relaxation.  
The peak maximum of this broad peak was taken as the secondary glass transition temperature, Tgβ 
(as shown in Figure 1 on the example of amorphous indomethacin, other examples are in the 
supporting information). The observed Tgα and Tgβ are from isochronal measurements at 1Hz, where 
the approximate DMA relaxation time is 0.159s. The broad peak was observed for all the amorphous 
drugs indicating that all the drugs possess local relaxations and hence, are mobile below their Tgα. It 
is worth noting that in some polymeric materials, there are multiple secondary relaxations and some 
are linked to side chain motions 31. However, in small drug molecules which do not contain such 
repeating units, as found in polymeric materials, the observed secondary relaxations may be arising 
from localized molecular motion 32 which has been identified as an intrinsic property of disordered 
molecular glasses 16. This type of mobility is termed Johari-Goldstein relaxation 31 and has been found 
in a terahertz spectroscopic study on amorphous organic molecules 33, in metallic glasses using DMA 
34 and in viscous liquids using dielectric spectroscopy 35. Other techniques that have been used in the 
study of glass transitions are Brillouin scattering 36, neutron scattering 37, Raman spectroscopy 38 and 
2H-NMR spin lattice relaxation 39 among others. However, DSC which is a well-established and 
comparatively simple technique, most often used in pharmaceutical development, cannot easily 
resolve the β-relaxation in amorphous drugs 19, as the change in heat capacity at that temperature may 
be below the detection limit. This has led to a focus on the Tgα especially in the amorphous drug 
community with only comparatively little work done on the Tgβ 40. It has been recently shown that a 
weak but distinct signal change of the β-relaxation process can be detected in the techniques 
mentioned above 41, and it is perhaps not surprising that this change may be below the detection limit 
of a DSC. However, Vyazovkin et al. detected Tgβ with DSC after annealing 40 and Oguni detected 
such transitions using specialized DSC equipment 42, but these have been more commonly interpreted 
by the wider community as to originate from potential cracks in the sample. 
Here, we report for the first time sub-Tgα relaxations of amorphous drugs measured via DMA. There 
is still debate regarding the fundamental physical mechanism governing the mobility below Tgα. A 
number of theories using concepts ranging from the so-called ‘island of mobility’16 to ‘caged 
dynamics’32, 43-45 have been proposed. Recently, an investigation into the origins of the molecular 
dynamics in disordered solids has suggested that the potential energy surface structure, i.e. energetic 
peaks and valleys, are directly responsible for the relaxation processes found in molecular glasses. 
Specifically, the glass transitions represent the points at which there is sufficient energy to overcome 
the potential barriers, leading to increased motion and thus increased molecular mobility. At 
temperatures below Tgα, the mobility is much more localized (i.e. intramolecular torsions and 
hindered rotations), and below Tgβ it was shown that these types of motion are frozen out. In this 
study, we show that a correlation exists between this sort of sub-Tgα molecular mobility and the onset 
of recrystallization of amorphous drugs.  
In order to investigate the onset of recrystallization, a set of the amorphous drugs was prepared 
(originally crystalline drugs were converted to their respective amorphous forms by QC) and were 
stored over phosphorus pentoxide, P2O5, (0% RH) at 296 K. The onset of recrystallization was 
monitored by X-ray powder diffraction (XRPD), in an attempt to establish a correlation between 
either the Tgα or Tgβ and the onset of recrystallization.  
The Tgα, observed by DMA as the peak maximum of the sharp peak in Figure 1, is often assumed to 
correlate with stability. However, when plotting the Tgα versus the onset of recrystallization (1/time) 
it is obvious (see Figure 2) that there is no clear relation between the Tgα and the physical stability of 
the amorphous drugs at the chosen storage condition. For example, nifedipine and indomethacin have 
similar molecular weight and Tgα but they do show vast difference in their recrystallization 
tendencies; the onset of recrystallization for nifedipine is 1 day and that of indomethacin is 30 days 
when stored at 0% RH, 298 K. However, the fact remains that the Tgα is important as it is the 
vitrification temperature. For pharmaceutical development of amorphous drugs, it remains an 
indispensable parameter as it determines the upper temperature limit for manufacturing and storage.  
The importance of Tgβ as determined by DMA for physical stability is shown in Figure 3. Clearly, 
there is a good correlation between Tgβ and the onset of recrystallization of the amorphous drugs. 
Drugs with lower Tgβ, e.g. nifedipine (Tgβ ≈ 89 K below storage temperature), tend to recrystallize 
earlier than those with higher Tgβ, e.g. Zent V that has Tgβ ≈ 75 K above the experimental storage 
temperature. As shown above, Tgβ represents the lower-limit of the thermal energy required to 
overcome potential energy barriers related to conformational rearrangement, increasing the molecular 
mobility. This increased mobility increases the probability that two neighboring molecules will move 
into a favorable (crystalline) packing motif, which could set off a chain of crystallization events. 
Therefore, storing amorphous drugs at temperatures above Tgβ may lead to increased molecular 
mobility, increased rate of nucleation and subsequently, increased propensity for crystallization. For 
an amorphous drug to be physically stable it is imperative that Tgβ ≥ Ts (storage temperature), as it 
has been clearly shown by the already amorphous (i.e. practically stable), zafirlukast, Na-
taurocholate, Zent X and Zent V, used in this study; all of them have a Tgβ at or above ambient 
temperature. If the Tgβ of the neat amorphous drug is at room temperature or higher, molecular 
mobility responsible for recrystallization is significantly reduced and the amorphous form is retained 
over long periods of time. Tgβ can therefore be thought of as the lowest temperature limit above which 
recrystallization might occur 21. This finding agrees with other studies that have found evidence of 
crystal nucleation at temperatures well below the Tgα as for example, in indomethacin where 
crystallization has been observed at temperature as low as Tgα - 55 K 21, or for 3,3'– dimethoxy- 4,4'-
bis(2,2-diphenylvinyl) biphenyl at Tgα -175 K 25 and for amorphous naproxen at Tgα - 89 K 19. In 
addition, stability of proteins has been found to correlate with β-relaxation processes 24 and small 
organic molecules (detail review in 13) have been shown to have a correlation with the β-relaxation 
time and crystallization kinetics.  
 
Figure 2: Lack of correlation between Tgα and the onset of recrystallization (1/time (/day)). At 
the chosen storage condition of 0% RH, 296 K, the Tgα does not provide adequate information 
on the physical stability.  
 
 
 
Figure 3: Correlation between Tgβ and onset of recrystallization (1/time (/day)).  At the 
experimental storage condition, there is a correlation between Tgβ and physical stability. 
 
As a rule of thumb, it has generally been assumed that molecular motion ceases when storing 
amorphous drugs at or below their Kauzmann temperature 46 which is estimated at 50 K below the 
Tgα  15, 47. This assumption may not be valid as shown on the example of the most unstable drug in our 
sample set, nifedipine which has Tgα at 322.5 K. Storing nifedipine at 278 K guarantees physical 
stability for less than 4 days and at 253 K for under 136 days. In Figure 4, it is shown that decreasing 
the storage temperature increases nifedipine’s resistance to recrystallization significantly. Therefore, 
physical stability increases with decreasing the storage temperature. From the results obtained, the 
“Tg -50 K rule of thumb” 15, 47 may be rephrased as; “at a storage temperature TS < Tgβ molecular 
motion responsible for recrystallization is reduced sufficiently, to render the amorphous form 
physically stable”. Although for some amorphous drugs, Tgβ may be close to “Tgα-50 K”, it should be 
mentioned, that in our experiments we did not find a relation between the molecular processes 
happening at Tgβ and Tgα. As an example, although nifedipine and indomethacin have similar Tgα 
(approx. 336 K), the difference between the individual Tgβ is well over 15 K. 
For recrystallization of amorphous drugs, Sibik et al. 19 and Ruggiero et al. 41 have hypothesized that 
below Tgβ molecules do not have enough energy to overcome potential energy barriers and hence 
recrystallization is not possible for the disordered molecules. This explanation then implies that at 
temperatures below Tgβ the system becomes confined to individual potential energy minima, 
effectively ‘locking’ the molecules in and preventing large scale conformational rearrangement 41, 48.  
This is in line with the suggestion by Middleton and Wales, where the lack of non-diffusive 
rearrangement 49 will result in no crystallization. Here we have provided experimental evidence 
(Figure 4 on NIF E) for this hypothesis. The amorphous form of the least physically stable of the nine 
drugs, nifedipine, is retained when stored at 193 K, i.e. below the Tgβ of this drug. Based on these 
experimental findings, it is justified that Tgβ is of importance compared to the relaxation time. 
 
 
Figure 4: Diffractograms of amorphous nifedipine (NIF) stored at 0 % RH and at different 
temperatures; NIF A was stored at 313 K, NIF B was stored at 296 K, NIF C was stored at 
278 K, NIF D 253 K and NIF E was stored at 193 K. 
 
Based on the observed correlation between Tgβ and the physical stability, an empirical correlation is 
proposed for predicting the physical stability of neat amorphous drugs stored at 0% RH. This 
empirical correlation, as shown in Figure 5, was created by fitting an exponential curve of the form 
𝑦 = 𝐴𝑒(−𝑥/𝑏) + 𝐶𝑒(−𝑥/𝑑) + 𝑦0  to the data in Figure 4, where y is the onset of recrystallization, x is 
Tgβ and A, b, C, d are constant values (fitting parameters are provided in supporting information). For 
celecoxib and nifedipine, that deviate somewhat from the proposed correlation, it was observed that 
the width of the peak associated with the β-relaxation in the DMA data was well over 50 K, whereas 
the other QC drugs were between 30-40 K (width of the β-relaxation of quench cooled drugs are 
shown in the supporting information). The broadness of the β-relaxation peak in the DMA data might 
imply that there is a wide temperature and energy range that the motions associated with the β-
relaxation are related to, thus inherent errors and deviations might be more expected for these 
materials in comparison to the others. From this empirical correlation, the physical stability of neat 
amorphous drugs can be estimated. The curve flattens from 296 K and for drug molecules that have 
a Tgβ above this temperature, molecular mobility at or below RT responsible for crystallization might 
be low. Amorphous drugs that show Tgβ at or above RT might therefore, be physically stable and can 
be considered for pharmaceutical development. Also, many metallic glasses have a high Tgβ (e.g. Tgβ 
for La56.16Ce14.04Ni19.8Al10 metallic glass is 399 K 50) and are practically stable at RT 34.  
 
 
 Figure 5: Based on the observed correlation, an empirical correlation for predicting the onset 
of recrystallization is proposed and drugs that have a Tgβ at or above ambient temperature 
(blue dashed line) are physically stable. 
CONCLUSION 
In summary, the relaxations in a set of amorphous drugs were characterized by DMA. The drugs 
exhibit mobility below their respective Tgα. When studying physical stability of amorphous drugs, the 
β-relaxation is the decisive parameter to provide adequate information on the onset of 
recrystallization. The study of this set of amorphous drugs has revealed a clear correlation between 
β-relaxation and physical stability, and an empirical correlation for predicting physical stability has 
been proposed for drugs stored at dry conditions.  
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